AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

TruGraf Contracted With Humana for In-network Coverage of Medicare Kidney Transplant Patients

July 7, 2021 GMT

LUXEMBOURG--(BUSINESS WIRE)--Jul 7, 2021--

Eurofins Transplant Genomics, Inc. (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is excited to announce the first national in-network contract for TruGraf, its proprietary gene expression test for subclinical acute rejection. Humana, a leading health care company that offers a wide range of insurance products and health and wellness services, will offer in-network coverage for the TruGraf blood gene expression test to its Medicare kidney transplant patients, effective August 1, 2021.

TruGraf is the first blood gene expression test approved by CMS/Medicare. TruGraf offers the earliest possible detection of “silent” subclinical acute rejection in kidney transplant patients with stable kidney function before organ injury and chronic acute rejection begins. This novel biomarker test offers transplant patients a non-invasive option for otherwise painful biopsy procedures, leading to detection of subclinical rejection, better long-term outcomes, and an improved quality of life.

ADVERTISEMENT

Humana will cover the TruGraf test for its Medicare Advantage, Medicare HMO, Medicare Network PFFS, Medicare POS, and Medicare PPO patients.

TGI is very pleased that Humana has extended in-network coverage for TruGraf, making this test available to its Medicare transplant patient population. TGI is committed to working in partnership with medical providers to make our non-invasive approach to improving transplant outcomes available to patients who can benefit from it.

About Transplant Genomics, Inc.

Eurofins Transplant Genomics, Inc. (“TGI”) is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy. Working alongside the transplant community and within the Eurofins family of companies, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status. Our flagship product is TruGraf, the only non-invasive blood test approved by CMS that offers the earliest possible detection of “silent” subclinical acute rejection in kidney transplant recipients with stable graft function. Test services are offered through TGI’s CLIA laboratory in Fremont, CA. TGI was acquired by Eurofins Scientific in 2019.

ADVERTISEMENT

Learn more about Transplant Genomics at https://trugraf.com/ and about Eurofins Scientific at https://www.eurofins.com/

View source version on businesswire.com:https://www.businesswire.com/news/home/20210707005635/en/

CONTACT: For further information:

Branden Morris

Transplant Genomics, Inc.

brandenmorris@eurofins-tgi.com

+1-510-745-4707

KEYWORD: NORTH AMERICA FRANCE UNITED STATES EUROPE LUXEMBOURG

INDUSTRY KEYWORD: BIOTECHNOLOGY SURGERY MEDICAL DEVICES OTHER HEALTH HEALTH

SOURCE: Eurofins Scientific SE

Copyright Business Wire 2021.

PUB: 07/07/2021 12:00 PM/DISC: 07/07/2021 12:01 PM

http://www.businesswire.com/news/home/20210707005635/en